Pharmas Join To Build Inflammation Biomarkers In Alzheimer's, Depression
Executive Summary
Drug firms exploring link between inflammation and central nervous system disorders are now sharing resources through public/private Biomarkers Consortium project.
You may also be interested in...
Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
More Alzheimer's Pain As J&J Pulls Plug On BACE Inhibitor
J&J's Janssen unit is ending development of atabecestat after serious elevations of liver enzymes were seen in some patients who received the drug, increasing doubts about the BACE inhibitor mechanism as an appropriate target.
Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance
US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.